TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37777018
Drug: Ritlecitinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (200 mg loading dose/50 mg daily)
Study: 37777018
Drug: Ritlecitinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (100 mg/50 mg daily)
Study: 37777018
Drug: Ritlecitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (50 mg daily)
Study: 37777018
Drug: Ritlecitinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (30 mg daily)
Study: 37777018
Drug: Ritlecitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (10 mg daily)
Study: 37777743
Drug: Empagliflozin (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (early treatment < 24 hours after PCI)
Study: 37777743
Drug: Empagliflozin (intermediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (intermediate treatment 24 to < 48 hours after PCI)
Study: 37777743
Drug: Empagliflozin (late
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (late treatment 48 to 72 hours after PCI)
Study: 37777832
Drug: Xevinapant 200
Normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xevinapant 200 mg/day on days 1-14 of a 3-week cycle
Study: 37777832
Drug: Xevinapant 200
Normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xevinapant 200 mg/day
Study: 37777827
Drug: Tremelimumab combined
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab combined with anti-PD-L1 durvalumab and chemotherapy
Study: 37778226
Drug: Truncated dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truncated dual antiplatelet therapy (DAPT)
Study: 37778356
Drug: Gradual, flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual, flexible antipsychotic reduction
Study: 37778358
Drug: Efgartigimod (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efgartigimod (10 mg/kg)
Study: 37779885
Drug: Combined quantitative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined quantitative pupillometry with neuron-specific enolase (NSE >60 μg L)
Study: 37779919
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRIN) plus radiation therapy
Study: 37780074
Drug: Dupilumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab treatment (discontinued)
Study: 37780234
Drug: Reduced-dose pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose pneumococcal conjugate vaccine schedules
Study: 37781132
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid dosage of 0.8 mg
Study: 37781132
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid dosages ranging from 0 mg to 2.4 mg
Study: 37781132
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid dosages of 0, 0.4, 0.6, 0.8, 1.2, 1.6, 2.0 mg to 2.4 mg
Study: 37781158
Drug: Ibrutinib and
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib and bortezomib combination therapy
Study: 37781158
Drug: Ibrutinib maintenance
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib maintenance after combination therapy
Study: 37781159
Drug: MAMMS (two-way
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAMMS (two-way SMS platform with MUAC tapes and weekly reminders)
Study: 37781161
Drug: AZD3759 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3759 at 200 mg bid
Study: 37781161
Drug: AZD3759 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3759 at 300 mg bid
Study: 37781161
Drug: AZD3759 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3759 (both doses combined)
Study: 37782145
Drug: MiniMed insulin
Normalized name: MiniMed Insulin Pump Reservoir 3 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiniMed insulin pump therapy
Study: 37782353
Drug: AG019 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG019 monotherapy (Phase 1b)
Study: 37782353
Drug: AG019 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG019 in combination with teplizumab (Phase 2a)
Study: 37782356
Drug: Serum UA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum UA above 240 μmol/l
Study: 37782421
Drug: Contrast-enhanced 2D
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced 2D T1-weighted gradient-echo sequences acquired at least 10 min after contrast injection (gadobutrol 0.1 mmol/kg)
Study: 37782888
Drug: Intratumoral LSAM-PTX
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral LSAM-PTX (15 mg/mL)
Study: 37783453
Drug: Cholera conjugate
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera conjugate vaccine (CCV) OSP:rTTHc
Study: 37783805
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo drug response profiling
Study: 37783805
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo resistance to chemotherapeutic drugs
Study: 37783805
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo response to chemotherapy
Study: 37783805
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo drug response profiles
Study: 37783970
Drug: Elranatamab monotherapy
Normalized name: elranatamab
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elranatamab monotherapy
Study: 37784053
Drug: EGYFIL™ topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGYFIL™ topical lotion
Study: 37784109
Drug: Screening frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening frequency (once vs. at least twice daily)
Study: 37784110
Drug: Enteral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral L-citrulline (5 g every 12 hours for 5 days)
Study: 37784197
Drug: Neuromuscular exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular exercise therapy program
Study: 37786390
Drug: Metformin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (maximum dose, 2500 mg)
Study: 37786396
Drug: Tirzepatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (5 mg, 10 mg, 15 mg)
Study: 37786451
Drug: Tocilizumab 6
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 6 mg/kg
Study: 37786451
Drug: Tocilizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (all doses)
Study: 37786680
Drug: Zotiraciclib (ZTR),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotiraciclib (ZTR), a CDK9 inhibitor
Study: 37787009
Drug: PEG-IFNa +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFNa + TDF (180 μg PEG-IFNa weekly plus 300 mg TDF once daily)
Study: 37787009
Drug: PEG-IFNa +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFNa + placebo (180 μg PEG-IFNa weekly plus placebo)
Study: 37787025
Drug: MAG-EPA (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG-EPA (3.75 g daily)
Study: 37787025
Drug: HOSO (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOSO (3.75 g daily)
Study: 38845180
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) plus best medical management
Study: 37787796
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with cuff pressure 20 mm Hg (n=751)
Study: 37787815
Drug: Integrative oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative oncology (IO) treatment program
Study: 37787888
Drug: Fixed-ratio combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-ratio combination (basal insulin + GLP-1RA)
Study: 37787888
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of basal insulin plus an SGLT-2 inhibitor (gliflo-combo)
Study: 37787941
Drug: 5-alpha-reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-alpha-reductase inhibitors (5-ARIs)
Study: 37787941
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (5-ARIs naïve)
Study: 37788412
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg canakinumab once every 3 weeks for 18 cycles
Study: 37788412
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg canakinumab
Study: 37788924
Drug: MAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAC treatment with macrolides, rifamycin, ethambutol, amikacin and/or fluoroquinolones
Study: 37788924
Drug: Drug exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug exposure
Study: 37790298
Drug: Neuromodulation (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulation (4 hours twice daily)
Study: 38183154
Drug: Implementation strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation strategies focusing on training, education, clinician support, and tailoring physical therapy interventions for telehealth delivery and cultural competency
Study: 37790451
Drug: Model combining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model combining time-on-treatment and rule-based volumes of CE and intratumoral Fluid
Study: 37790490
Drug: ATL-DC +
Normalized name: ATL-104
DrugBank: ATL-104 (DB05670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATL-DC + TLR agonist (poly-ICLC)
Study: 37790490
Drug: ATL-DC +
Normalized name: ATL-104
DrugBank: ATL-104 (DB05670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATL-DC + TLR agonist (resiquimod)
Study: 37790695
Drug: Oral-motor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-motor therapy programme for one month
Study: 37791419
Drug: Rapid Antiretroviral
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Antiretroviral Therapy (ART) initiation after diagnosis of AHI
Study: 37791765
Drug: pBI-11 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pBI-11 DNA vaccine via Tropis biojector
Study: 37792065
Drug: Ruxolitinib (RUX)
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib (RUX) administered according to the Summary of Product Characteristics
Study: 37792612
Drug: Sarilumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab (200 mg, twice-monthly subcutaneous injection) plus a 14-week prednisone taper
Study: 37792612
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus a 52-week prednisone taper
Study: 37793101
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment, details on dosage and duration not available.
Study: 37793306
Drug: Acupressure (ST25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure (ST25, CV12, CV6) for twice-daily therapy at 4 min per intervention for 7 days
Study: 37793771
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 2.5 mg/kg intravenously every 21 days
Study: 37793771
Drug: Pomalidomide 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4.0 mg daily (days 1-21) and dexamethasone 40.0 mg weekly in a 28-day cycle
Study: 37793853
Drug: SGN-B7H4V (vedotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-B7H4V (vedotin ADC) as monotherapy
Study: 37793853
Drug: SGN-B7H4V (vedotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-B7H4V (vedotin ADC) in combination with anti-PD-1 agent
Study: 37793919
Drug: Tele-prehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-prehabilitation group using a tablet, two accelerometers, and a balance board (Khymeia, Padova, Italy)
Study: 37794185
Drug: PTPN2/PTPN1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTPN2/PTPN1 inhibitor ABBV-CLS-484
Study: 37794275
Drug: Oral Lichen
Normalized name: Lichen prunastri
DrugBank: Evernia prunastri (DB14172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Lichen Planus Symptom Severity Measure (OLPSSM)
Study: 37794431
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (intradermal administration)
Study: 37794472
Drug: ICS tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS tapering regimen (initial ICS dose reduced by 50% for 8 weeks followed by total ICS removal)
Study: 37794472
Drug: ICS tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS tapering regimen
Study: 37794659
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (INCS) - 220 μg triamcinolone acetonide twice daily for 14 days prior to nasal allergen challenge (NAC)
Study: 37794659
Drug: NAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC with no treatment intervention
Study: 37794659
Drug: NAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC with 14 days pre-treatment with saline nasal spray (placebo)
Study: 37794830
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment for bile acid diarrhoea
Study: 37794830
Drug: C4 >
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C4 > 46 ng/mL
Study: 37794830
Drug: Decision tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision tree combining C4 ≥ 31 ng/mL with ≥1.1 daily watery stools (Bristol type 6 and 7)
Study: 37794830
Drug: Logistic regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic regression model including C4, sum of measured stool bile acids, and daily watery stools
Study: 37794845
Drug: AbobotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA treatment
Study: 37794870
Drug: Daily prompts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily prompts to complete 10,000 steps
Study: 37794870
Drug: Hourly prompts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly prompts to stand following inactivity
Study: 37794870
Drug: Daily instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily instructions to read AHA guidelines
Study: 37795521
Drug: Oral pre-exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine prescribed at baseline.
Study: 37795883
Drug: Closed-Loop Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-Loop Insulin Delivery System
Study: 37795976
Drug: ALVAC-HIV (vCP2438)
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B
Study: 37795976
Drug: ALVAC-HIV (vCP2438)
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59
Study: 37795976
Drug: ALVAC-HIV (vCP2438)
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with AS01B
Study: 37796017
Drug: Telehealth group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Study: 37796117
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with no injections (Control group)
Study: 37796398
Drug: Fruquintinib 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 3 mg QD 3/1 (n=7)
Study: 37796398
Drug: Fruquintinib 5
Normalized name: fruquintinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5 mg QD 3/1 (n=7)
Study: 37796398
Drug: Fruquintinib 5
Normalized name: fruquintinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5 mg RP2D (n=6)
Study: 37796417
Drug: ARR on
Normalized name: Barr Only CenterPointLock 2-Piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARR on interfering medications
Study: 37796417
Drug: ARR off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARR off interfering medications
Study: 37796417
Drug: ARR on
Normalized name: Barr Only CenterPointLock 2-Piece
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARR on interfering medications (threshold 10 pg/μIU)
Study: 37796417
Drug: ARR off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARR off interfering medications (threshold 10 pg/μIU)
Study: 37796513
Drug: Tislelizumab, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab, 200 mg intravenously every 3 weeks
Study: 37796513
Drug: Sorafenib tosylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib tosylate, 400 mg orally twice daily
Study: 37796540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CBN
Study: 37796540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CBN + 10 mg CBD
Study: 37796540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CBN + 20 mg CBD
Study: 37796540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CBN + 100 mg CBD
Study: 37797387
Drug: Capecitabine (Cap)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (Cap) 2000 mg/m² day 1-14 q3w for 6 cycles plus ibandronate (Ib) 50 mg p.o. daily or 6 mg intravenous q4w for 2 years
Study: 37797632
Drug: Cadonilimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab at 6 mg/kg and 10 mg/kg every 2 weeks (dose escalation phase)
Study: 37797632
Drug: Cadonilimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab at 6 mg/kg and a fixed dose of 450 mg every 2 weeks (dose expansion phase)
Study: 37797632
Drug: Cadonilimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab at 6 mg/kg every 2 weeks (phase 2)
Study: 37797733
Drug: Bintrafusp Alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp Alfa (BA) with concurrent chemoradiotherapy (cCRT) followed by BA
Study: 37797733
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with concurrent chemoradiotherapy (cCRT) followed by durvalumab
Study: 37798422
Drug: Sulfonylurea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea treatment for carriers of novel HNF1A variants
Study: 37798468
Drug: Reparixin 1200
Normalized name: Réparixine
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparixin 1200 mg three times daily for up to 21 days
Study: 37798538
Drug: M8891 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: M8891 (a selective and reversible inhibitor of methionine aminopeptidase 2)
Study: 37798650
Drug: HB-adMSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-adMSC therapy (5 intravenous infusions of 2 × 10^6 cells)
Study: 37798723
Drug: NTHi vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi vaccine candidate genes (pd, pe, pilA) and Mcat gene (uspA2)
Study: 37798723
Drug: NTHi vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi vaccine candidate genes (pd, pilA)
Study: 37798756
Drug: Fascia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia therapy along with conventional physical therapy (hot pack, strengthening, stretching)
Study: 37798756
Drug: Fascial manipulation
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fascial manipulation treatment with conventional physical therapy
Study: 37798801
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg for 5 days)
Study: 37798801
Drug: Colchicine (day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (day 1: 1.5 mg; days 2-5: 1 mg)
Study: 37798860
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control neurodevelopmental therapy (NDT)
Study: 38233885
Drug: IVIg (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (2.0 g/kg every 4 weeks for 16 weeks)
Study: 37799613
Drug: IVIg (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (2.0 g/kg for 6 additional cycles during Extension Period)
Study: 37799724
Drug: Omicron-adapted vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omicron-adapted vaccine
Study: 37800112
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with moderate-intensity rosuvastatin (RE 10) and ezetimibe (10 mg)
Study: 37800374
Drug: Direct transport
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct transport to a comprehensive stroke center (CSC) prioritizing endovascular therapy